Burjeel Holdings and Axiom Space reveal Suite Ride study results, showing diabetes monitoring tools work in space, opening future missions to diabetic astronauts.
NEW YORK/ABU DHABI: In a groundbreaking step for both space exploration and healthcare, UAE-based Burjeel Holdings, in collaboration with Axiom Space, has unveiled results from its Suite Ride diabetes research conducted aboard the International Space Station (ISS) during Axiom Mission 4.
The study confirmed that everyday diabetes tools—continuous glucose monitors (CGMs) and insulin pens—can function reliably in microgravity, offering accurate real-time readings and safe dosage delivery. This marks the first time such devices have been tested aboard the ISS, creating a path for astronauts with diabetes to participate in space missions.
Announcing the results in New York, Burjeel Holdings declared its ambition to send the first astronaut with diabetes into space. The findings were revealed publicly at Times Square and celebrated at the Burjeel Institute for Global Health, with Dr. Shamsheer Vayalil, Chairman of Burjeel Holdings, and Tejpaul Bhatia, CEO of Axiom Space, in attendance.
“This isn’t just about space exploration,” said Gavin D’Elia, Global Head of Pharma at Axiom Space. “It’s about showing people that a diagnosis does not mean the end of their dreams. Together, we are advancing the potential to fly the first astronaut with diabetes.”
The Suite Ride initiative delivered several firsts: the first continuous glucose monitoring on the ISS, the first insulin pens sent to the station, and the first validation of glucose monitoring across multiple methods in space. Beyond spaceflight, the findings carry immense potential for improving remote healthcare on Earth, including in offshore oil rigs, rural communities, and other extreme environments.
Dr. Mohammad Fityan, Chief Medical Officer at Burjeel Medical City, explained, “Besides opening the door for astronauts with diabetes, these findings will transform care on Earth. From 250 miles above Earth to 25 miles offshore, we are pioneering new models of remote healthcare.”
The initiative follows a legacy of space-driven medical innovation. In the 1970s, NASA’s Mars lander technology helped inspire the first wearable insulin pump. Now, Suite Ride continues that tradition, bringing both inclusivity in space travel and innovation in chronic disease care.
As the UAE advances its space ambitions, Burjeel Holdings and Axiom Space are committed to strengthening space health and building a more inclusive future in global healthcare innovation.
